Every Form 4 that Takeda Pharmaceutical Company Limited (TAK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TAK filings page.
Platford Giles Richard reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Giles Richard Platford, President IBU, received a grant of 72,124 American Depositary Shares on April 27, 2026 as a performance-based restricted stock unit (RSU) award at no cash cost to him.
The award was determined by the Compensation Committee using performance metrics including core revenue, core operating profit and important R&D milestones from an RSU grant originally made on July 1, 2023. Following this award, Platford directly holds 297,363 American Depositary Shares, including 166,744 RSUs scheduled to vest on July 1, 2026 (116,762 shares), July 1, 2027 (32,396 shares) and July 1, 2028 (17,586 shares).
Pignagnoli Agosti Marcello reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Marcello Pignagnoli Agosti received an award of 27,740 American Depositary Shares on April 27, 2026. The grant reflects performance-based restricted stock units tied to core revenue, core operating profit, and key R&D milestones.
After this award, he directly holds 172,348 American Depositary Shares, including 81,590 restricted stock units. These RSUs are scheduled to vest in tranches on July 1, 2026 (52,250 shares), July 1, 2027 (19,798 shares), and July 1, 2028 (9,542 shares).